Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

Autolus Therapeutics (AUTL) Cost of Revenue (2024 - 2025)

Autolus Therapeutics' Cost of Revenue history spans 2 years, with the latest figure at $25.3 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 122.45% year-over-year to $25.3 million; the TTM value through Dec 2025 reached $96.4 million, up 746.31%, while the annual FY2025 figure was $96.4 million, 746.31% up from the prior year.
  • Cost of Revenue reached $25.3 million in Q4 2025 per AUTL's latest filing, down from $28.6 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $28.6 million in Q3 2025 to a low of $11.4 million in Q4 2024.